Osteoporosis in postmenopausal women: Considerations in prevention and treatment: (Women's Health Series)

Southern Medical Journal

Volumn 106, Issue 12, 2013, Pages 698-706

  Sanders, Suzanne ^a,b   Geraci, Stephen A ^a,b  

^a G V SONNY MONTGOMERY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b East Tennessee State University   (United States)

Author keywords

menopause; osteoporosis; prevention; screening; treatment

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; ESTROGEN; GESTAGEN; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE MINERAL; CALCIUM INTAKE; COMPUTER ASSISTED TOMOGRAPHY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; ESTROGEN THERAPY; EXERCISE; FEMALE; GASTROINTESTINAL DISEASE; HIP FRACTURE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; KIDNEY FAILURE; LIFESTYLE; MUSCULOSKELETAL PAIN; PATIENT CARE; POSTMENOPAUSE OSTEOPOROSIS; RASH; REVIEW; RISK REDUCTION; SCREENING TEST; SPINE FRACTURE; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION;

ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 84890385453     PISSN: 00384348     EISSN: 15418243     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3182a0df8b     Document Type: Review

References (70)

1. US Department of Health and Human Services. Bone health and osteoporosis: A report of the Surgeon General. http://www.surgeongeneral. gov/library/reports/bonehealth/content.html. Published 2004. Accessed September 20, 2012.
2. National Osteoporosis Foundation. Fast facts. http://www.nof.org/connect/ get-the-facts. Accessed September 20, 2012.
3. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. http://www.nof.org/files/nof/public/content/file/344/ upload/159.pdf. Published 2010. Accessed September 20, 2012.
4. US Preventive Services Task Force. Screening for osteoporosis: Recommendation statement. Am Fam Physician 2011;83:1197-1200.
5. Management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause 2010; 17:25-54. 5a. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. http://nof.org/hcp/clinicians-guide. Published 2013. Accessed July 12, 2013.
6. International Society for Clinical Densitometry. 2007 ISCD official positions brochure. http://www.iscd.org/wp-content/themes/iscd/pdfs/official- positions/ISCD2007OfficialPositions-Adult.pdf. Published October 2007. Accessed September 20, 2012.
7. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis (WHO technical report series 843). Ann Rheum Dis 1995;54:548.
8. Saag KG, Geusens P. Progress in osteoporosis and fracture prevention: Focus on postmenopausal women. Arthritis Res Ther 2009;11:251.
9. NationalOsteoporosis Foundation. NationalOsteoporosis Foundation (NOF) /International Society for Clinical Densitometry (ISCD) recommendations to DXA manufacturers for FRAX implementation. http://www.nof.org/files/nof/public/ content/resource/862/files/392.pdf. Published 2010. Accessed September 20, 2012.
10. Krall EA, Dawson-Hughes B. Smoking and bone loss among postmenopausal women. J BoneMiner Res 1991;6:331-338.
11. Krall EA, Dawson-Hughes B. Smoking increases bone loss and decreases intestinal calcium absorption. J Bone Miner Res 1999;14:215-220.
12. Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: A metaanalysis. Osteoporos Int 2005;16:155-162.
13. Baron JA, Farahmand BY, Weiderpass E, et al. Cigarette smoking, alcohol consumption, and risk of hip fracture in women. Arch Intern Med 2001; 161:983-988.
14. Felson DT, Zhang Y, HannanMT, et al. Alcohol intake and bone mineral density in elderly men and women. The Framingham Study. Am J Epidemiol 1995;142:485-492.
15. Tucker KL, Jugdaohsingh R, Powell JJ, et al. Effects of beer, wine, and liquor intakes on bone mineral density in older men and women. Am J Clin Nutr 2009;89:1188-1196.
16. Kool B, Ameratunga S, Robinson E, et al. The contribution of alcohol to falls at home among working-aged adults. Alcohol 2008;42:383-388.
17. Kanis JA, Johansson H, Johnell O, et al. Alcohol intake as a risk factor for fracture. Osteoporos Int 2005;16:737-742.
18. Rapuri PB, Gallagher JC, Kinyamu HK, et al. Caffeine intake increases the rate of bone loss in elderly women and interacts with vitamin D receptor genotypes. Am J Clin Nutr 2001;74:694-700.
19. Hallstrom H,Wolk A, Glynn A, et al. Coffee, tea, and caffeine consumption in relation to osteoporotic fracture risk in a cohort of Swedish women. Osteoporos Int 2006;17:1055-1064.
20. Hansen SA, Folsom AR, Kushi LH, et al. Association of fractures with caffeine and alcohol in postmenopausal women: The Iowa Women's Health Study. Public Health Nutr 2000;3:253-261.
21. Nordin BE. The effect of calcium supplementation on bone loss in 32 controlled trials in postmenopausal women. Osteoporos Int 2009;20: 2135-2143.
22. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354: 669-683.
23. Dawson-Hughes B. Calcium plus vitamin D and the risk of fractures. N Engl J Med 2006;354:2285-2287.
24. Prince RL,DevineA,Dhaliwal SS, et al. Effects of calcium supplementation on clinical fracture and bone structure: Results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med 2006;166: 869-875.
25. Avenell A, Gillespie WJ, Gillespie LD, et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2009;15: CD000227.
26. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementationYa meta-analysis of randomized controlled trials. JAMA 2005;293:2257-2264.
27. National Research Council. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington, DC, The National Academies Press, 1997.
28. Hathcock JN, Shao A, Vieth R, et al. Risk assessment for vitamin D. Am J Clin Nutr 2007;85:6-18.
29. Bolland MJ, Grey A, Avenell A, et al. Calcium supplements with or without vitamin D and risk of cardiovascular events: Reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011;342:d2040.
30. Body JJ, Bergmann P, Boonen S, et al. Extraskeletal benefits and risks of calcium, vitamin D, and anti-osteoporosis medications. Osteoporos Int 2012;23:S1YS23.
31. Curhan GC, Willett WC, Rimm EB, et al. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 1993;328:833-838.
32. Curhan GC,Willett WC, Speizer FE, et al. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 1997;126:497-504.
33. Curhan CG, Willett WC, Knight EL, et al. Dietary factors and the risk of incident kidney stones in younger women: Nurses' Health Study II. Arch Intern Med 2004;164:885-891.
34. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-281.
35. Malabanan A, Veronikis IE, HolickMF. Redefining vitamin D insufficiency. Lancet 1998;351:805-806.
36. Holick MF, Siris ES, Binkley N, et al. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005;90:3215-3224.
37. Lips P, Hosking D, Lippuner K, et al. The prevalence of vitamin D inadequacy amongst women with osteoporosis: An international epidemiological investigation. J Intern Med 2006;260:245-254.
38. Prince RL, Austin N, Devine A, et al. Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. Arch Intern Med 2008;168:103-108.
39. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: A meta-analysis. JAMA 2004;291:1999-2006.
40. Janssen HC, Samson MM, Verhaar HJ. Vitamin D deficiency, muscle function, and falls in elderly people. Am J Clin Nutr 2002;75:611-615.
41. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006;81:353-373.
42. Polidoulis I, Beyene J, Cheung AM. The effect of exercise on pQCT parameters of bone structure and strength in postmenopausal womenVa systematic review and meta-analysis of randomized controlled trials. Osteoporos Int 2012;23:39-51.
43. Bocalini DS, Serra AJ, dos Santos L, et al. Strength training preserves the bone mineral density of postmenopausal women without hormone replacement therapy. J Aging Health 2009;21:519-527.
44. Bemben DA, Bemben MG. Dose-response effect of 40 weeks of resistance training on bone mineral density in older adults. Osteoporos Int 2011;22: 179-186.
45. Zehnacker CH, Bemis-Dougherty A. Effect of weighted exercises on bone mineral density in post menopausal women. A systematic review. J Geriatr Phys Ther 2007;30:79-88.
46. Martyn-St James M, Carroll S.Meta-analysis of walking for preservation of bone mineral density in postmenopausal women. Bone 2008;43: 521-531.
47. Tolomio S, Ermolao A, Lalli A, et al. The effect of a multicomponent dual-modality exercise program targeting osteoporosis on bone health status and physical function capacity of postmenopausal women. J Women Aging 2010;22:241-254.
48. Teixeira LE, Silva KN, Imoto AM, et al. Progressive load training for the quadriceps muscle associated with proprioception exercises for the prevention of falls in postmenopausal women with osteoporosis: A randomized controlled trial. Osteoporos Int 2010;21:589-596.
49. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
50. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
51. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295: 1647-1657.
52. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348: 1535-1541.
53. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282: 1344-1352.
54. Reginster J, MinneHW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91.
55. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-340.
56. Chestnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-1249.
57. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356: 1809-1822.
58. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 1999; 282:637-645.
59. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441.
60. Cummings SR, SanMartin J,McClungMR, et al.Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-765.
61. Chesnut CH3rd, Silverman S, AndrianoK, et al.Arandomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-276.
62. Reginster J. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 2011;71:65-78.
63. PDR Network. Physician's Desk Reference. http://www.pdr.net. Published 2012. Accessed September 13, 2012.
64. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-1491.
65. Shannon J, Shannon J, Modelevsky S, et al. Bisphosphonates and osteonecrosis of the jaw. J Am Geriatr Soc 2011;59:2350-2355.
66. Meier RP, Perneger TV, Stern R, et al. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 2012;172:930-936.
67. Green J, Czanner G, Reeves G, et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: Case-control analysis within a UK primary care cohort. BMJ 2010;341:c4444.
68. Cardwell CR, Abnet CC, Cantwell MM, et al. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010;304: 657-663.
69. Dore RK. The RANKL pathway and denosumab. Rheum Dis Clin North Am 2011;37:433-452.
70. Traynor K. Experts recommend against calcitonin-salmon for postmenopausal osteoporosis. Am J Health Syst Pharm 2013;70:64-Y650.